Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2025)

Cytosorbents' Asset Writedowns and Impairment history spans 14 years, with the latest figure at -$136000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at -$136000.0 for Q4 2025, up 31.31% from a year ago — trailing twelve months through Dec 2025 was $40000.0 (down 65.22% YoY), and the annual figure for FY2025 was $40000.0, down 65.22%.
  • Asset Writedowns and Impairment for Q4 2025 was -$136000.0 at Cytosorbents, down from -$77000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $641226.0 in Q4 2023 to a low of -$421057.0 in Q3 2022.
  • The 5-year median for Asset Writedowns and Impairment is $4013.5 (2021), against an average of $40091.0.
  • The sharpest move saw Asset Writedowns and Impairment tumbled 6960.96% in 2022, then surged 5760.47% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at -$6649.0 in 2021, then crashed by 181.59% to -$18723.0 in 2022, then surged by 3524.8% to $641226.0 in 2023, then crashed by 130.88% to -$198000.0 in 2024, then skyrocketed by 31.31% to -$136000.0 in 2025.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at -$136000.0, -$77000.0, and $251110.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.